The autoimmune kidney disorder primary membranous nephropathy (MN) is commonly caused antibodies directed against the PLA2R receptor of the kidney. In many patients with MN, kidney transplantation is ultimately needed. However, in MN patients having PLA2R antibodies, the risk of relapse following transplantation is high. Recent guidelines for the management of glomerular diseases have highlighted how a non-invasive strategy, PLA2R antibody testing, can be used to evaluated the risk of relapse following kidney transplantation. In this webinar, Dr. Jean Francis speaks about the significance of kidney transplant in MN patients and highlights the testing strategy for pre- and post-transplant evaluation.
Jean Francis, MD
Medical Director of Kidney Transplantation
Boston University Medical Center (BUMC)
To view this webinar, please complete the following form.
2024 EUROIMMUN US
